260 related articles for article (PubMed ID: 12424708)
1. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome.
Sánchez-Corral P; Pérez-Caballero D; Huarte O; Simckes AM; Goicoechea E; López-Trascasa M; de Córdoba SR
Am J Hum Genet; 2002 Dec; 71(6):1285-95. PubMed ID: 12424708
[TBL] [Abstract][Full Text] [Related]
2. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome.
Pérez-Caballero D; González-Rubio C; Gallardo ME; Vera M; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
Am J Hum Genet; 2001 Feb; 68(2):478-84. PubMed ID: 11170895
[TBL] [Abstract][Full Text] [Related]
3. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions.
Józsi M; Heinen S; Hartmann A; Ostrowicz CW; Hälbich S; Richter H; Kunert A; Licht C; Saunders RE; Perkins SJ; Zipfel PF; Skerka C
J Am Soc Nephrol; 2006 Jan; 17(1):170-7. PubMed ID: 16338962
[TBL] [Abstract][Full Text] [Related]
4. The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome.
Martinez-Barricarte R; Pianetti G; Gautard R; Misselwitz J; Strain L; Fremeaux-Bacchi V; Skerka C; Zipfel PF; Goodship T; Noris M; Remuzzi G; de Cordoba SR;
J Am Soc Nephrol; 2008 Mar; 19(3):639-46. PubMed ID: 18235085
[TBL] [Abstract][Full Text] [Related]
5. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.
Lehtinen MJ; Rops AL; Isenman DE; van der Vlag J; Jokiranta TS
J Biol Chem; 2009 Jun; 284(23):15650-8. PubMed ID: 19351878
[TBL] [Abstract][Full Text] [Related]
6. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome.
Heinen S; Sanchez-Corral P; Jackson MS; Strain L; Goodship JA; Kemp EJ; Skerka C; Jokiranta TS; Meyers K; Wagner E; Robitaille P; Esparza-Gordillo J; Rodriguez de Cordoba S; Zipfel PF; Goodship TH
Hum Mutat; 2006 Mar; 27(3):292-3. PubMed ID: 16470555
[TBL] [Abstract][Full Text] [Related]
7. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity.
Blom AM; Bergström F; Edey M; Diaz-Torres M; Kavanagh D; Lampe A; Goodship JA; Strain L; Moghal N; McHugh M; Inward C; Tomson C; Frémeaux-Bacchi V; Villoutreix BO; Goodship TH
J Immunol; 2008 May; 180(9):6385-91. PubMed ID: 18424762
[TBL] [Abstract][Full Text] [Related]
8. Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding.
Volokhina E; Westra D; Xue X; Gros P; van de Kar N; van den Heuvel L
Pediatr Nephrol; 2012 Sep; 27(9):1519-24. PubMed ID: 22669319
[TBL] [Abstract][Full Text] [Related]
9. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome.
Ferreira VP; Herbert AP; Cortés C; McKee KA; Blaum BS; Esswein ST; Uhrín D; Barlow PN; Pangburn MK; Kavanagh D
J Immunol; 2009 Jun; 182(11):7009-18. PubMed ID: 19454698
[TBL] [Abstract][Full Text] [Related]
10. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities.
Pechtl IC; Kavanagh D; McIntosh N; Harris CL; Barlow PN
J Biol Chem; 2011 Apr; 286(13):11082-90. PubMed ID: 21270465
[TBL] [Abstract][Full Text] [Related]
11. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome.
Hyvärinen S; Meri S; Jokiranta TS
Blood; 2016 Jun; 127(22):2701-10. PubMed ID: 27006390
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants.
Dekkers G; Brouwer MC; Jeremiasse J; Kamp A; Biggs RM; van Mierlo G; Lauder S; Katti S; Kuijpers TW; Rispens T; Jongerius I
J Immunol; 2020 Oct; 205(7):1778-1786. PubMed ID: 32848031
[TBL] [Abstract][Full Text] [Related]
13. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome.
Jokiranta TS; Jaakola VP; Lehtinen MJ; Pärepalo M; Meri S; Goldman A
EMBO J; 2006 Apr; 25(8):1784-94. PubMed ID: 16601698
[TBL] [Abstract][Full Text] [Related]
14. Recognition of malondialdehyde-modified proteins by the C terminus of complement factor H is mediated via the polyanion binding site and impaired by mutations found in atypical hemolytic uremic syndrome.
Hyvärinen S; Uchida K; Varjosalo M; Jokela R; Jokiranta TS
J Biol Chem; 2014 Feb; 289(7):4295-306. PubMed ID: 24344133
[TBL] [Abstract][Full Text] [Related]
15. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome.
Martínez-Barricarte R; Heurich M; López-Perrote A; Tortajada A; Pinto S; López-Trascasa M; Sánchez-Corral P; Morgan BP; Llorca O; Harris CL; Rodríguez de Córdoba S
Mol Immunol; 2015 Aug; 66(2):263-73. PubMed ID: 25879158
[TBL] [Abstract][Full Text] [Related]
16. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome.
Manuelian T; Hellwage J; Meri S; Caprioli J; Noris M; Heinen S; Jozsi M; Neumann HP; Remuzzi G; Zipfel PF
J Clin Invest; 2003 Apr; 111(8):1181-90. PubMed ID: 12697737
[TBL] [Abstract][Full Text] [Related]
17. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation.
Nilsson SC; Karpman D; Vaziri-Sani F; Kristoffersson AC; Salomon R; Provot F; Fremeaux-Bacchi V; Trouw LA; Blom AM
Mol Immunol; 2007 Mar; 44(8):1835-44. PubMed ID: 17084897
[TBL] [Abstract][Full Text] [Related]
18. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree.
Esparza-Gordillo J; Jorge EG; Garrido CA; Carreras L; López-Trascasa M; Sánchez-Corral P; de Córdoba SR
Mol Immunol; 2006 Apr; 43(11):1769-75. PubMed ID: 16386793
[TBL] [Abstract][Full Text] [Related]
19. Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome-A pedigree revisited.
Johnson SA; Williams JM; Hakobyan S; Richards A; Perkins SJ; Marchbank KJ; Goodship TH; Morgan BP; Taylor CM; Savage CO
Mol Immunol; 2010 Apr; 47(7-8):1585-91. PubMed ID: 20304497
[TBL] [Abstract][Full Text] [Related]
20. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d.
Bhattacharjee A; Lehtinen MJ; Kajander T; Goldman A; Jokiranta TS
Mol Immunol; 2010 May; 47(9):1686-91. PubMed ID: 20378178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
